Table 2. Results of Kaplan–Meier analysis for predicting PFS.
|
PFS
|
||||
|---|---|---|---|---|
| Parameter | Group | Critical events | Median (months) | Log-rank test |
| Sex | Female | 6/6 | 12 | 0.455 |
| Male | 9/10 | 10 | ||
| Age at start therapy | ⩽60 | 8/8 | 12 | 0.671 |
| >60 | 7/8 | 10 | ||
| Chemotherapy | FolFox | 10/11 | 10 | 0.810 |
| FolFiri | 5/5 | 12 | ||
| Detection of liver metastasis | Synchronous | 6/6 | 12 | 0.495 |
| Metachronous | 9/10 | 10 | ||
| Chemonaive | Yes | 10/10 | 10 | 0.928 |
| No | 5/6 | 10 | ||
| Number of liver lesions | ⩽3 | 7/8 | 10 | 0.266 |
| >3 | 8/8 | 10 | ||
| Diameter of the largest lesion | <5 cm | 12/12 | 10 | 0.177 |
| ⩾5 cm | 3/4 | 11 | ||
| Primary tumour location | Colon | 13/14 | 10 | 0.732 |
| Rectum | 2/2 | 11 | ||
| R0 resection liver metastases | Yes | 12/13 | 11 | 0.267 |
| No | 3/3 | 10 | ||
| Liver-only metastases | Yes | 13/14 | 11 | 0.064 |
| No | 2/2 | 6 | ||
| Time between last chemotherapy and surgery | ⩽7 weeks | 9/10 | 14 | 0.013 |
| >7 weeks | 6/6 | 9 | ||
Abbreviation: PFS=progression-free survival. The bold value indicates statistical significance.